{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"191","upperLimit":"191","value":"191"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Blood samples were collected at specified timepoints. Results reported as nanograms/milliliter (ng/mL).","dispersionType":"Full Range","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic Population: all participants who received ≥1 dose of avapritinib and had had \\>3 post-dose concentrations collected.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1 (1 hour postdose) (28 days/cycle)","title":"Maximum Plasma Concentration (Cmax) of a Single Dose of Avapritinib","type":"SECONDARY","unitOfMeasure":"ng/mL"}